BACKGROUND: Guillain-Barré syndrome (GBS) is a serious, acute paralytic neuropathy of autoimmune aetiology, usually associated with a previous infection. The current study aims to estimate the costs of GBS associated with Zika virus (ZIKV) infection in Brazil. METHODS: A cost-of-illness study was conducted from the perspective of the Brazilian public health system (Sistema Único de Saúde [SUS]) and Brazilian society for the year 2016. Direct and indirect costs were estimated by a mixed macrocosting and microcosting approach. RESULTS: The total cost of ZIKV-associated GBS in Brazil was US$11 997 225.85, consisting of the costs of symptomatic ZIKV infection before onset of GBS (direct costs US$2011.51, indirect costs US$19 780.53) and the costs that followed development of GBS (direct costs US$4 722 980.89, indirect costs US$7 252 452.92). The cost of treatment with human immunoglobulin (US$3 263 210.50) and the cost of productivity losses associated with potential years of working life lost due to early mortality (US$4 398 551.72) were particularly noteworthy. CONCLUSIONS: These findings suggest that ZIKV-associated GBS is costly to Brazil, especially due to productivity losses and hospitalization. This highlights the importance of investing in the prevention of ZIKV infection and in the care of patients with GBS.
BACKGROUND: Guillain-Barré syndrome (GBS) is a serious, acute paralytic neuropathy of autoimmune aetiology, usually associated with a previous infection. The current study aims to estimate the costs of GBS associated with Zika virus (ZIKV) infection in Brazil. METHODS: A cost-of-illness study was conducted from the perspective of the Brazilian public health system (Sistema Único de Saúde [SUS]) and Brazilian society for the year 2016. Direct and indirect costs were estimated by a mixed macrocosting and microcosting approach. RESULTS: The total cost of ZIKV-associated GBS in Brazil was US$11 997 225.85, consisting of the costs of symptomatic ZIKVinfection before onset of GBS (direct costs US$2011.51, indirect costs US$19 780.53) and the costs that followed development of GBS (direct costs US$4 722 980.89, indirect costs US$7 252 452.92). The cost of treatment with human immunoglobulin (US$3 263 210.50) and the cost of productivity losses associated with potential years of working life lost due to early mortality (US$4 398 551.72) were particularly noteworthy. CONCLUSIONS: These findings suggest that ZIKV-associated GBS is costly to Brazil, especially due to productivity losses and hospitalization. This highlights the importance of investing in the prevention of ZIKVinfection and in the care of patients with GBS.
Authors: Paulo Rufalco-Moutinho; Lorena Aparecida Gonçalves de Noronha; Tatyane de Souza Cardoso Quintão; Tayane Ferreira Nobre; Ana Paula Sampaio Cardoso; Daiani Cristina Cilião-Alves; Marco Aurélio Bellocchio Júnior; Mateus de Paula von Glehn; Rodrigo Haddad; Gustavo Adolfo Sierra Romero; Wildo Navegantes de Araújo Journal: Parasit Vectors Date: 2021-12-19 Impact factor: 3.876
Authors: Luíza Morais de Matos; Ariely Teotonio Borges; Aline Barbosa Palmeira; Vinicius Moreira Lima; Ernane Pires Maciel; Rubens Nelson Morato Fernandez; João Pedro Lima Mendes; Gustavo Adolfo Sierra Romero Journal: Rev Soc Bras Med Trop Date: 2022-04-08 Impact factor: 2.141
Authors: Jose Angel Regla-Nava; Ying-Ting Wang; Camila R Fontes-Garfias; Yang Liu; Thasneem Syed; Mercylia Susantono; Andrew Gonzalez; Karla M Viramontes; Shailendra Kumar Verma; Kenneth Kim; Sara Landeras-Bueno; Chun-Teng Huang; Daniil M Prigozhin; Joseph G Gleeson; Alexey V Terskikh; Pei-Yong Shi; Sujan Shresta Journal: Cell Rep Date: 2022-04-12 Impact factor: 9.995